These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 37667046)

  • 1. Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.
    Wang Q; Liang Z; Ren H; Dong Y; Yin Y; Wang Q; Liu W; Wang B; Han N; Li Y; Li Y
    Ann Hematol; 2023 Nov; 102(11):3061-3074. PubMed ID: 37667046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of NCCN (2015) risk stratification on prognosis of patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Wang H; Liu HX; Wang T; Tong CR; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):44-49. PubMed ID: 28219225
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.
    Zhou W; Chen G; Gong D; Gao Y; Yu L
    Front Oncol; 2023; 13():1138853. PubMed ID: 36845681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
    Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
    Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.
    Cho BS; Yahng SA; Min GJ; Park S; Park SS; Shin SH; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Transplant Cell Ther; 2021 Sep; 27(9):774.e1-774.e12. PubMed ID: 34082159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
    Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
    BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
    Meur GL; Plesa A; Larcher MV; Fossard G; Barraco F; Loron S; Balsat M; Ducastelle-Leprêtre S; Gilis L; Thomas X; Ghesquières H; Tigaud I; Hayette S; Huet S; Sujobert P; Renault M; Thérèse RM; Michallet M; Labussière-Wallet H; Heiblig M
    Transplant Cell Ther; 2023 Jan; 29(1):38.e1-38.e9. PubMed ID: 36108977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
    Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
    Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.
    Cao XY; Chen JQ; Wang H; Ma W; Liu WW; Zhang FF; Xue S; Dong L; Liu T; Zhao XZ; Liu CC; Xu X; He Y; Wang L; Wang JL
    Ann Med; 2023 Dec; 55(1):388-400. PubMed ID: 36629738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of pre-transplant course on prognosis of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia].
    Liu XJ; Huang XJ; Xu LP; Liu KY; Zhang XH; Yan CH; Wang Y
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):182-186. PubMed ID: 30929382
    [No Abstract]   [Full Text] [Related]  

  • 18. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
    Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
    Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
    Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.